tert-Butyl 4-(4-aminobenzoyl)piperazine-1-carboxylate

Catalog No. :
ACWEPC791
CAS No. :
350684-49-0
Molecular Formula :
C16H23N3O3
Molecular Weight :
305.38

IUPAC Name:tert-butyl 4-(4-aminobenzoyl)piperazine-1-carboxylate

tert-Butyl 4-(4-aminobenzoyl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$83.00Login to see priceIn stockInquiry
5g95%$333.00Login to see priceIn stockInquiry
25g95%$1279.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(4-aminobenzoyl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(4-aminobenzoyl)piperazine-1-carboxylate
MDL No.T192915
Molecular FormulaC16H23N3O3
Molecular Weight305.38
SMILESO=C(N1CCN(C(C2=CC=C(N)C=C2)=O)CC1)OC(C)(C)C
InChI KeyPCJKGZGOTDJFBX-UHFFFAOYSA-N
Synonymtert-butyl 4-(4-aminobenzoyl)tetrahydro-1(2H)-pyrazinecarboxylate | 10Y-0700 | SCHEMBL110336 | FT-0679976 | 2-Methyl-2-propanyl 4-(4-aminobenzoyl)-1-piperazinecarboxylate | AB3285 | DTXSID00376914 | J-019853 | MFCD06659531 | tert-Butyl4-(4-aminobenzoyl)te
CAS No.350684-49-0
PubChem CID2763355

Safety Data

Pictogram
Health hazard
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACWEPC791 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRVCG084 route compound structure diagram
    ACRVCG084509073-62-5 In Stock
  2. Then
  3. ACWEPC791 route product structure diagram
    ACWEPC791350684-49-0 In Stock
Inquiry

2. ACWEPC791 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACNFPB351 route compound structure diagram
    ACNFPB351138-84-1 In Stock
  4. Then
  5. ACWEPC791 route product structure diagram
    ACWEPC791350684-49-0 In Stock
Inquiry

Comments (0)